# Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

> **NCT05386550** · PHASE3 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 166 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Xevinapant
- **RADIATION:** IMRT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05386550
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-06
- **Primary completion:** 2024-08-27
- **Final completion:** 2024-08-27
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** The study was terminated by sponsor as the development program was discontinued due to outcome of phase III Trilynx study.
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386550, "Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05386550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*